241 related articles for article (PubMed ID: 11464890)
1. Somatostatin receptor type 2 gene expression in neuroblastoma, measured by competitive RT-PCR, is related to patient survival and to somatostatin receptor imaging by indium -111-pentetreotide.
Orlando C; Raggi CC; Bagnoni L; Sestini R; Briganti V; La Cava G; Bernini G; Tonini GP; Pazzagli M; Serio M; Maggi M
Med Pediatr Oncol; 2001 Jan; 36(1):224-6. PubMed ID: 11464890
[TBL] [Abstract][Full Text] [Related]
2. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors.
Briganti V; Sestini R; Orlando C; Bernini G; La Cava G; Tamburini A; Raggi CC; Serio M; Maggi M
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2385-91. PubMed ID: 9815638
[TBL] [Abstract][Full Text] [Related]
3. Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell lines and primary tumors using competitive reverse transcription-polymerase chain reaction.
Sestini R; Orlando C; Peri A; Tricarico C; Pazzagli M; Serio M; Pagani A; Bussolati G; Granchi S; Maggi M
Clin Cancer Res; 1996 Oct; 2(10):1757-65. PubMed ID: 9816127
[TBL] [Abstract][Full Text] [Related]
4. Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome.
Raggi CC; Maggi M; Renzi D; Calabrò A; Bagnoni ML; Scaruffi P; Tonini GP; Pazzagli M; De Bernardi B; Bernini G; Serio M; Orlando C
J Clin Endocrinol Metab; 2000 Oct; 85(10):3866-73. PubMed ID: 11061551
[TBL] [Abstract][Full Text] [Related]
5. Type-2 somatostatin receptor mRNA levels in breast and colon cancer determined by a quantitative RT-PCR assay based on dual label fluorogenic probe and the TaqMan technology.
Pinzani P; Orlando C; Raggi CC; Distante V; Valanzano R; Tricarico C; Maggi M; Serio M; Pazzagli M
Regul Pept; 2001 Jun; 99(2-3):79-86. PubMed ID: 11384768
[TBL] [Abstract][Full Text] [Related]
6. Influence of 17q gain and promoter polymorphisms on mRNA expression of somatostatin receptor type 2 in neuroblastoma.
Simi L; Pinzani P; Raggi CC; Pazzagli M; Orlando C
Clin Chim Acta; 2007 Sep; 384(1-2):149-54. PubMed ID: 17678886
[TBL] [Abstract][Full Text] [Related]
7. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
[TBL] [Abstract][Full Text] [Related]
8. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.
Kaneko S; Ohira M; Nakamura Y; Isogai E; Nakagawara A; Kaneko M
J Cancer Res Clin Oncol; 2007 Mar; 133(3):185-92. PubMed ID: 17028906
[TBL] [Abstract][Full Text] [Related]
9. Absence of somatostatin receptor expression in vivo is correlated to di- or tetraploid 1p36-deleted neuroblastomas.
Schilling FH; Ambros PF; Bihl H; Martinsson T; Ambros IM; Borgström P; Jacobsson H; Falkmer UG; Treuner J; Kogner P
Med Pediatr Oncol; 2001 Jan; 36(1):56-60. PubMed ID: 11464907
[TBL] [Abstract][Full Text] [Related]
10. In-111 pentetreotide scintigraphy in patients with neuroblastoma. Comparison with I-131 MIBG, N-Myc oncogene amplification, and patient outcome.
Shalaby-Rana E; Majd M; Andrich MP; Movassaghi N
Clin Nucl Med; 1997 May; 22(5):315-9. PubMed ID: 9152532
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I
Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590
[TBL] [Abstract][Full Text] [Related]
12. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
13. The high level of hCDC10 gene expression in neuroblastoma may be associated with favorable characteristics of the tumor.
Nagata T; Takahashi Y; Asai S; Ishii Y; Mugishima H; Suzuki T; Chin M; Harada K; Koshinaga S; Ishikawa K
J Surg Res; 2000 Aug; 92(2):267-75. PubMed ID: 10896833
[TBL] [Abstract][Full Text] [Related]
14. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.
Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM
Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155
[TBL] [Abstract][Full Text] [Related]
15. Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma.
Manohar CF; Salwen HR; Brodeur GM; Cohn SL
Genes Chromosomes Cancer; 1995 Nov; 14(3):196-203. PubMed ID: 8589036
[TBL] [Abstract][Full Text] [Related]
16. Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.
van Wezel EM; Decarolis B; Stutterheim J; Zappeij-Kannegieter L; Berthold F; Schumacher-Kuckelkorn R; Simon T; Fiocco M; van Noesel MM; Caron HN; van der Schoot CE; Hero B; Tytgat GAM
Eur J Cancer; 2016 Feb; 54():149-158. PubMed ID: 26796600
[TBL] [Abstract][Full Text] [Related]
17. Comparison of MIBG and pentetreotide scintigraphy in children with neuroblastoma. Is the expression of somatostatin receptors a prognostic factor?
Kropp J; Hofmann M; Bihl H
Anticancer Res; 1997; 17(3B):1583-8. PubMed ID: 9179198
[TBL] [Abstract][Full Text] [Related]
18. Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa.
Casini Raggi C; Calabrò A; Renzi D; Briganti V; Cianchi F; Messerini L; Valanzano R; Cameron Smith M; Cortesini C; Tonelli F; Serio M; Maggi M; Orlando C
Clin Cancer Res; 2002 Feb; 8(2):419-27. PubMed ID: 11839658
[TBL] [Abstract][Full Text] [Related]
19. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
[TBL] [Abstract][Full Text] [Related]
20. Neuron-specific hel-N1 and HuD as novel molecular markers of neuroblastoma: a correlation of HuD messenger RNA levels with favorable prognostic features.
Ball NS; King PH
Clin Cancer Res; 1997 Oct; 3(10):1859-65. PubMed ID: 9815574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
